Sonia Lain

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2247596/publications.pdf

Version: 2024-02-01

69	5,840	117625	98798
papers	citations	34 h-index	67 g-index

70	70	70	7391
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Awakening guardian angels: drugging the p53 pathway. Nature Reviews Cancer, 2009, 9, 862-873.	28.4	805
2	SUMO-1 modification activates the transcriptional response of p53. EMBO Journal, 1999, 18, 6455-6461.	7.8	602
3	Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator. Cancer Cell, 2008, 13, 454-463.	16.8	470
4	Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation. Molecular and Cellular Biology, 2000, 20, 8458-8467.	2.3	337
5	Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nature Biotechnology, 2015, 33, 415-423.	17.5	237
6	Phosphorylation of the Protein Kinase Mutated in Peutz-Jeghers Cancer Syndrome, LKB1/STK11, at Ser431 by p90RSK and cAMP-dependent Protein Kinase, but Not Its Farnesylation at Cys433, Is Essential for LKB1 to Suppress Cell Growth. Journal of Biological Chemistry, 2001, 276, 19469-19482.	3.4	234
7	p53-based Cancer Therapy. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001222-a001222.	5.5	206
8	SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells. Cell Stem Cell, 2014, 15, 431-446.	11.1	187
9	Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Current Biology, 1997, 7, 71-80.	3.9	179
10	Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene, 2001, 20, 4972-4983.	5.9	168
11	Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide from p16CDKN2/INK4A. Current Biology, 1996, 6, 84-91.	3.9	161
12	The complete nucleotide sequence of plum pox potyvirus RNA. Virus Research, 1989, 13, 157-172.	2.2	139
13	Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair, 2009, 8, 1215-1224.	2.8	130
14	Novel Cambinol Analogs as Sirtuin Inhibitors: Synthesis, Biological Evaluation, and Rationalization of Activity. Journal of Medicinal Chemistry, 2009, 52, 2673-2682.	6.4	120
15	Therapeutic exploitation of the p53 pathway. Trends in Molecular Medicine, 2002, 8, S38-S42.	6.7	112
16	Nucleotide sequence of the 3' terminal region of plum pox potyvirus RNA. Virus Research, 1988, 10, 325-341.	2.2	89
17	Homologous potyvirus and flavivirus proteins belonging to a superfamily of helicase-like proteins. Gene, 1989, 82, 357-362.	2.2	89
18	RNA helicase activity of the plum pox potyvirus Cl protein expressed inEscherichia coli. Mapping of an RNA binding domain. Nucleic Acids Research, 1995, 23, 1327-1332.	14.5	83

#	Article	IF	Citations
19	Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene, 1998, 16, 587-596.	5.9	80
20	Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene, 1999, 18, 7378-7386.	5.9	78
21	Proteolytic activity of the plum pox potyvirus Nla-like protein in Escherichia coli. Virology, 1989, 170, 362-369.	2.4	77
22	Infectious in Vitro transcripts from a plum pox potyvirus cDNA clone. Virology, 1990, 177, 710-716.	2.4	77
23	Chapter 5 Sirtuins and p53. Advances in Cancer Research, 2009, 102, 171-195.	5.0	68
24	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget, 2010, 1, 639-650.	1.8	65
25	Differential expression and functionally co-operative roles for the retinoblastoma family of proteins in epidermal differentiation. Oncogene, 1998, 17, 949-957.	5.9	63
26	A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nature Communications, 2018, 9, 1107.	12.8	63
27	An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle, 2012, 11, 1851-1861.	2.6	57
28	Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget, 2010, 1, 639-50.	1.8	52
29	Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorganic and Medicinal Chemistry, 2012, 20, 1779-1793.	3.0	47
30	Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle, 2011, 10, 1590-1598.	2.6	46
31	Pilot screening programme for small molecule activators of p53. International Journal of Cancer, 2005, 115, 701-710.	5.1	45
32	Identification of the initiation codon of plum pox potyvirus genomic RNA. Virology, 1991, 185, 544-552.	2.4	44
33	Tenovin-D3, a Novel Small-Molecule Inhibitor of Sirtuin SirT2, Increases p21 (CDKN1A) Expression in a p53-Independent Manner. Molecular Cancer Therapeutics, 2013, 12, 352-360.	4.1	38
34	Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS Letters, 2003, 536, 220-224.	2.8	36
35	Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive. Journal of Clinical Investigation, 2018, 128, 4115-4131.	8.2	35
36	Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2. Molecular Cancer Therapeutics, 2013, 12, 471-480.	4.1	34

#	Article	IF	Citations
37	Small molecule activators of the p53 response. Journal of Molecular Cell Biology, 2019, 11, 245-254.	3.3	34
38	Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Scientific Reports, 2013, 3, 1275.	3.3	33
39	Oligomerization of the Human ARF Tumor Suppressor and Its Response to Oxidative Stress. Journal of Biological Chemistry, 2003, 278, 18720-18729.	3.4	30
40	Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. Oncotarget, 2015, 6, 16488-16506.	1.8	30
41	Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer, 2014, 13, 116.	19.2	28
42	Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes. International Journal of Cancer, 2007, 120, 2317-2324.	5.1	26
43	Determination of polyprotein processing sites by amino terminal sequencing of nonstructural proteins encoded by plum pox potyvirus. Virus Research, 1990, 15, 97-106.	2.2	25
44	Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase. Cell Chemical Biology, 2018, 25, 309-317.e4.	5.2	25
45	Modulating pyrimidine ribonucleotide levels for the treatment of cancer. Cancer & Metabolism, 2020, 8, 12.	5.0	25
46	Proteolytic activity of the plum pox potyvirus NIa-protein on excess of natural and artificial substrates inEscherichia coli. FEBS Letters, 1989, 257, 269-273.	2.8	21
47	Mass Spectrometry Reveals the Direct Action of a Chemical Chaperone. Journal of Physical Chemistry Letters, 2018, 9, 4082-4086.	4.6	21
48	Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs. Oncotarget, 2011, 2, 274-276.	1.8	20
49	p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP. Cell Cycle, 2012, 11, 4563-4569.	2.6	19
50	p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes. Molecular Carcinogenesis, 2000, 29, 251-262.	2.7	17
51	N1-Benzyl substituted cambinol analogues as isozyme selective inhibitors of the sirtuin family of protein deacetylases. MedChemComm, 2011, 2, 611.	3.4	16
52	Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability. Journal of Medicinal Chemistry, 2020, 63, 3915-3934.	6.4	15
53	Characterization, chemical optimization and anti-tumor activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle, 2008, 7, 3417-3427.	2.6	14
54	cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response. Cell Cycle, 2016, 15, 1267-1275.	2.6	13

#	Article	IF	Citations
55	DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance. IScience, 2021, 24, 102494.	4.1	11
56	Nucleotide sequence of a nucleoside triphosphate phosphohydrolase gene from African swine fever virus. Virus Research, 1993, 30, 63-72.	2.2	8
57	Discovery and Validation of SIRT2 Inhibitors Based on Tenovin-6: Use of a 1H-NMR Method to Assess Deacetylase Activity. Molecules, 2012, 17, 12206-12224.	3.8	8
58	Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. Journal of Biological Chemistry, 2020, 295, 17935-17949.	3.4	8
59	Proteolytic activity of plum pox virus-tobacco etch virus chimeric NIaproteases. FEBS Letters, 1991, 281, 67-72.	2.8	7
60	Functional characterization of novel germline TP53 variants in Swedish families. Clinical Genetics, 2019, 96, 216-225.	2.0	7
61	If p53 can't do it, ask p73. Cell Cycle, 2008, 7, 3287-3291.	2.6	6
62	Numerical and Experimental Analysis of the p53-mdm2 Regulatory Pathway. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2010, , 266-284.	0.3	6
63	Leptomycin B induces apoptosis in cells containing the whole HPV 16 genome. International Journal of Oncology, 2009, 35, 649-56.	3.3	4
64	Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. PLoS ONE, 2018, 13, e0195956.	2.5	4
65	Drug discovery in the p53 field. Seminars in Cancer Biology, 2010, 20, 1-2.	9.6	2
66	Novel p53-Based Therapies: Strategies and Future Prospects. , 2007, , 353-376.		1
67	Pharmacological Inhibition Of The SIRT1 Deacetylase With The Small Molecule Inhibitor Tenovin-6 Enhances Ablation Of FLT3-ITD+ LSC In Combination With TKI Treatment. Blood, 2013, 122, 2685-2685.	1.4	1
68	231 INVITED Activation of p53 by small molecules from fish to man. European Journal of Cancer, Supplement, 2006, 4, 75.	2.2	0
69	Upstream Targets in the p53 Pathway. , 2013, , 209-229.		0